Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Comparision between Beta Drugs IPO and IRIS Business IPO.
Beta Drugs IPO is a SME Fixed Price Issue IPO proposed to list at NSE SME while IRIS Business IPO is a SME Fixed Price Issue proposed to list at BSE SME.
| Beta Drugs IPO | IRIS Business IPO | |
|---|---|---|
| Logo |  |
 |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price Issue | Fixed Price Issue |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Pantomath Capital Advisors Pvt Ltd | Pantomath Capital Advisors Pvt Ltd |
| Registrar | Link Intime India Private Ltd | Link Intime India Private Ltd |
| Market Maker | ||
| DRHP | ||
| RHP | RHP  |
RHP |
| Anchor Investor | ||
| IPO Allotment URL |
The total issue size of Beta Drugs IPO is up to ₹19.52 Cr whereas the issue size of the IRIS Business IPO is up to ₹16.01 Cr. The final issue price of Beta Drugs IPO is ₹85.00 per share and of IRIS Business IPO is ₹34.00 per share.
| Beta Drugs IPO | IRIS Business IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ₹85.00 per share | ₹34.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1600 shares | 4000 shares |
| Fresh Issue Size | ||
| Fresh Issue Size (Amount) | ||
| OFS Issue Size | ||
| OFS Issue Size (Amount) | ||
| Issue Size Total | 22,96,000 shares | 50,04,000 shares |
| Issue Size Total (Amount) | up to ₹19.52 Cr | up to ₹16.01 Cr |
Beta Drugs IPO opens on Sep 29, 2017, while IRIS Business IPO opens on Sep 29, 2017. The closing date of Beta Drugs IPO and IRIS Business IPO is Oct 04, 2017, and Oct 04, 2017, respectively.
| Beta Drugs IPO | IRIS Business IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Sep 29, 2017 | Sep 29, 2017 |
| Issue Close | Oct 04, 2017 | Oct 04, 2017 |
| Basis Of Allotment (Tentative) | ||
| Initiation of Refunds (Tentative) | ||
| Credit of Share (Tentative) | ||
| Listing date (Tentative) | ||
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Beta Drugs IPO P/E ratio is , as compared to IRIS Business IPO P/E ratio of .
| Beta Drugs IPO | IRIS Business IPO | |
|---|---|---|
| Financial | ||
| Promoter Shareholding (Pre-Issue) | ||
| Promoter Shareholding (Post-Issue) | ||
| P/E Ratio | ||
| Market Cap | ||
| ROE | ||
| ROCE | ||
| Debt/Equity | ||
| EPS | ||
| RoNW |
In the Beta Drugs IPO retail investors (RII) are offered while in IRIS Business IPO retail investors are offered . Qualified institutional buyers (QIB) are offered in Beta Drugs IPO and in IRIS Business IPO.
| Beta Drugs IPO | IRIS Business IPO | |
|---|---|---|
| Anchor Investor Reserveration | ||
| Market Maker Reserveration | ||
| QIB | ||
| NII | ||
| RII | ||
| Employee | ||
| Others | ||
| Total |
Beta Drugs IPO subscribed in total, whereas IRIS Business IPO subscribed .
| Beta Drugs IPO | IRIS Business IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | ||
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | ||
| Employee (times) | ||
| Other (times) | ||
| Total (times) |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
